Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

BNT3214 · PM8102

Bispecific antibody · developed by BioNTech

Phase 1/2 Most advanced trial
BNTX Developer
1 Registered trials

What is BNT3214?

BNT3214 is an investigational bispecific antibody studied in Advanced Solid Tumor Cancer.

At a glance

Also known as
PM8102
Drug type
Bispecific antibody
Therapy area
Oncology
Developer
BioNTech SE (BNTX)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07455734 Phase 1/2 Advanced Solid Tumor Cancer Recruiting BNTX

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Advanced Solid Tumor Cancer

More from BioNTech

Follow BNTX, the company behind BNT3214

See BNTX's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

BNTX catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.